Avricore Health has announced that its engineering team integrated real-time reporting platform HealthTab and Abbott Diagnostics’ molecular PCR point-of-care device, ID Now.
The team was led by Avricore Health chief technology officer Rodger Seccombe.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The platform can potentially transmit Covid-19 test results automatically from the instrument to patients, healthcare units, and key agencies.
It will lead to drastically increasing data sharing speed and accuracy, as well as reduced workload.
Healthtab has a patient-facing web-portal and can directly integrate data into already deployed Covid-19 contact tracing apps.
With the portal, healthcare units and agencies can receive real-time case reporting to simplify contact tracing, identify outbreaks, and improve resource use.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSeccombe said: “Thanks to the technical team at the manufacturer, we were able to build and test this interface quickly and seamlessly.
“We’re excited to be able to offer an automated point-of-care data management solution for community-based testing sites that don’t have the information systems or technical resources you find in a hospital or medical laboratory.”
Avricore plans to receive agreements with jurisdictions, deploying approximately 3,800 ID Now devices and more than eight million tests that are being supplied by the Government of Canada.
The devices and tests can add testing capacity in rural and indigenous communities, long-term care units, and hospitals as they can carry out high-quality molecular tests onsite.
Avricore Health CEO Hector Bremner said: “The combination of high-quality instruments and real-time reporting makes point-of-care test deployment faster and more reliable than ever.
“We’ve been hearing from those on the frontlines that this is overdue, and we are really proud to now offer this critical service.”
Earlier this month, Health Canada approved Abbott’s sensor-based glucose monitoring technology, FreeStyle Libre 2, for adults and children aged four and above with diabetes.
